Psychedelic Science Institute

What Psychedelic Science Institute does

Psychedelic Science Institute (PSI), operating through its TRIP Clinics brand, is a California-based clinical organization that delivers psychedelic-assisted mental health care and serves as a clinical trial site for investigational psychedelic compounds. Formed in 2023 from the merger of the Pacific Neuroscience Institute's TRIP Center and the California Center for Psychedelic Therapy (CCPT), PSI runs two clinic locations in Los Angeles (Hollywood and Santa Monica) with a combined nine treatment rooms, employing a multidisciplinary team of licensed psychiatrists, psychotherapists, and neuroscientists. Its core commercial offering is Ketamine-Assisted Psychotherapy (KAP), the only federally available prescription psychedelic, delivered via intramuscular injection in conjunction with structured preparation and integration sessions using a proprietary set-and-setting methodology. Supporting services include individual psychotherapy, psychedelic integration therapy, and psychiatric medication management; telehealth is offered within California for non-dosing services.

The organization also operates FDA-grade clinical trial infrastructure, including IRB-experienced staff, EMR and CTMS systems, and rapid site start-up capabilities, and is currently supporting or has completed 15 clinical trials as a research site for biotech sponsors including Usona Institute, MindMed, Compass Pathways, Lykos Therapeutics (MAPS PBC), Atai Life Sciences, Cybin, Reunion Neuroscience, and Beckley Psytech, spanning psilocybin, LSD, MDMA, and DMT programs in depression, anxiety, and PTSD. PSI has emphasized diversity in trial recruitment, reporting 69% BIPOC and 29% LGBTQIA+ representation at its Hollywood site.

PSI's business model is predominantly self-pay professional services. KAP initial evaluations are priced at $550 for 90 minutes, dosing sessions at $600 (90 minutes plus 30 minutes recovery), individual psychotherapy at $250 per 50 minutes, integration at $250-$550 per hour, and medication management at $250-$300 per visit. A $150 deposit is required to hold initial appointments and superbills are provided for potential out-of-network insurance reimbursement, but PSI does not contract with insurers. The organization is a privately held LLC, has not disclosed external funding, and is independently led by clinician-founders. Go-to-market is driven by a formal provider referral program, direct patient inquiries, clinical trial recruitment, educational content, and a multi-channel presence including peer-reviewed publications and podcast appearances.

Name

Psychedelic Science Institute

Legal name

Psychedelic Science Institute, LLC

Website

https://psychedelicsci.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

11–50 employees

Short description

Psychedelic Science Institute operates TRIP Clinics in Los Angeles, delivering self-pay ketamine-assisted psychotherapy, integration, and medication management, while serving as a clinical trial site for psilocybin, LSD, MDMA, and DMT programs with biotech sponsors.

Ownership category

akta.pro rank

Product category

Mental Health Services

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420), Offices of Physicians, Mental Health Specialists (621112)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Outpatient Mental Health Clinics & Counseling Centers (HLAFACAA)

akta.pro secondary industry

Psychiatry & Medication Management Platforms (HLALAEAB)

Keywords

• Ketamine-assisted psychotherapy
• Psychedelic clinical trials
• Mental health treatment
• Psychedelic integration therapy
• Psychiatric medication management

Headquarters

HQ city

Los Angeles

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Ketamine-Assisted Psychotherapy (KAP): Direct patient revenue from ketamine-assisted psychotherapy sessions including initial evaluation ($550) and dosing sessions ($600). Treatment typically involves 8 initial sessions twice weekly for four weeks plus maintenance. Self-pay model with superbills provided for potential insurance reimbursement.
2. Psychotherapy Services: Individual psychotherapy sessions at $250 per 50-minute session with some sliding scale options available.
3. Psychedelic Integration Therapy: Integration counseling services at $250-550/hour depending on area of expertise.
4. Medication Management: Psychiatric medication management at $300 for 30-minute initial evaluation and $250 for follow-up appointments.
5. Clinical Trial Operations: Revenue from conducting clinical trials as a research site for biotech and pharmaceutical companies including Usona, MindMed, Compass Pathways, Lykos, Cybin, and others. Trial participation costs may be covered by study sponsors.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Psychedelic Science Institute operates TRIP Clinics in Los Angeles (Santa Monica and Hollywood) providing ketamine-assisted psychotherapy for depression, trauma, anxiety, and chronic pain, supported by individual psychotherapy, psychedelic integration therapy, and psychiatric medication management. PSI also functions as an FDA-grade clinical trial site for investigational psychedelic compounds (psilocybin, LSD, MDMA, DMT) sponsored by leading biotech and pharmaceutical companies.

Product overview

Psychedelic Science Institute (PSI) operates TRIP Clinics, a dual-location clinic network in Los Angeles (Santa Monica and Hollywood) offering psychedelic-based mental health care and clinical research. The core offerings include Ketamine-Assisted Psychotherapy (KAP) as the primary commercially available treatment, and Clinical Trials evaluating investigational psychedelics (psilocybin, LSD, DMT, MDMA) for various mental health conditions. Supporting services include Psychotherapy, Psychedelic Integration Therapy, and Medication Management. PSI also provides a Psychedelic Learning Center with educational content on psychedelics and psychedelic-assisted therapy.

Differentiator

Problem solved

Functional benefit

Products and services

• TRIP Clinics PSI's primary clinic brand offering psychedelic-assisted psychotherapy and clinical trial services at two Los Angeles locations (Santa Monica and Hollywood). Provides ketamine-assisted psychotherapy, clinical trials, integration therapy, psychotherapy, and medication management.
• Ketamine-Assisted Psychotherapy (KAP) FDA-approved ketamine treatment combined with psychotherapy for depression, anxiety, trauma, and suicidal ideation, administered via intramuscular injection with preparatory and integration sessions. Structured program typically involving 8 initial sessions twice weekly for four weeks plus maintenance.
• Clinical Trials Investigational psychedelic medicine trials for psilocybin, LSD, DMT, and MDMA targeting depression, anxiety, PTSD, and other mental health conditions, conducted at both clinic locations with FDA-grade infrastructure, IRB-experienced staff, and EMR + CTMS systems.
• Psychotherapy
• Psychedelic Integration Therapy Non-judgmental therapy supporting individuals in processing and making meaning from psychedelic experiences using somatic, mindfulness, and creative modalities. Sessions priced at $250-550/hour depending on area of expertise.
• Medication Management Ongoing psychiatric medication supervision and adjustment by licensed medical providers for depression, anxiety, PTSD, ADHD, and mood disorders. Initial evaluation at $300 (30 minutes) and follow-up appointments at $250.

Quantifiable outcome

• 11,000+ ketamine-assisted psychotherapy sessions delivered
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Usona InstitutecoreStrategic or Co-development PartnerPSI serves as a clinical trial site for Usona's psilocybin research for major depressive disorder. PSI has completed Usona's Phase 2 psilocybin trial (2023) and is conducting the Phase 3 uASPIRE PSIL301 trial.
• MindMedcoreStrategic or Co-development PartnerPSI is a clinical trial site for MindMed's LSD-based treatments including MM120 for generalized anxiety disorder (Phase 2 and Phase 3 Panorama trial) and major depressive disorder (Emerge and ASCEND trials).
• Compass PathwayscoreStrategic or Co-development PartnerPSI served as a clinical trial site for Compass Pathways' COMP360 psilocybin Phase 3 trial for treatment-resistant depression (COMP005, 2023-25).
• Lykos Therapeutics (MAPS PBC)coreStrategic or Co-development PartnerPSI has participated in multiple Lykos/MAPS clinical trials for MDMA-assisted therapy including Phase 2 (MP16), Phase 3 MAPP1 and MAPP2 trials, and epigenetic regulation substudy for PTSD.
• Atai Life SciencescoreStrategic or Co-development PartnerPSI is conducting the DMT Phase 2 trial (Elumina VLS-01-203) for treatment-resistant depression at the Santa Monica clinic.
• CybincoreStrategic or Co-development PartnerPSI is serving as a clinical trial site for Cybin's psilocybin analog CYB003 Phase 3 trial for major depressive disorder at the Hollywood clinic.
• Reunion NeurosciencecoreStrategic or Co-development PartnerPSI is conducting the RECLAIM RE104-203 trial for generalized anxiety disorder evaluating a psilocybin-like compound at the Santa Monica clinic.
• Beckley PsytechminorStrategic or Co-development PartnerListed as a past and current research partner in PSI's collaborator network.
• Thank You Life (Nonprofit)minorOthersPSI is partnered with Thank You Life, a nonprofit on a mission to revolutionize mental healthcare and eliminate financial barriers to psychedelic therapy. Donations support the Community Access Fund for psychedelic-assisted therapy accessibility.

Scale indicators5 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Compass Pathways: Public biotech developing COMP360 psilocybin for treatment-resistant depression. Listed sponsor of PSI's clinical trial work; broader psychedelic developer with delivery model (drug + therapy) that competes indirectly for the same end patients once approved.
• atai Life Sciences: Public psychedelic biotech platform holding multiple pipeline programs (including Cybin and a DMT candidate run through PSI). Comparable as a sponsor-of-trials peer and ultimately as a broader developer-of-psychedelic-medicines counterparty for PSI's clinic network.
• Usona Institute: Nonprofit sponsor of psilocybin research in major depressive disorder. Active trial partner running Phase 2 and Phase 3 trials through PSI sites; comparable to PSI from a sponsor-of-trials perspective.
• MindMed: Public biotech developing MM120 (LSD) for anxiety and depression. Active trial sponsor using PSI as a clinical site and pursuing FDA approval for psychedelic-based therapy that would route patients through provider networks like PSI's clinics.
• Lykos Therapeutics (MAPS PBC): Developer of MDMA-assisted therapy for PTSD. PSI has participated in multiple MAPS/Lykos trials, and Lykos is a comparable biotech sponsor with eventual commercial distribution ambitions that would touch the same provider network PSI operates within.

Others

• Osmind: Mental health practice infrastructure platform serving ketamine and interventional psychiatry clinics with EMR, billing, and outcomes tracking. Functions as an enabling technology provider for clinics like PSI rather than a direct clinical competitor.

Direct peers

• Journey Clinical: Provider-focused psychedelic therapy platform that trains and supports ketamine prescribers and integration therapists across the US. Operates in the same outpatient psychedelic medicine category with overlapping clinical protocols and patient population.
• Field Trip Health: Operated a network of ketamine-assisted psychotherapy clinics across North America with a similar 'set and setting' treatment model targeting depression and anxiety. The closest comparable clinic-network peer, although the company has been winding down US clinic operations.
• Mindbloom: Direct-to-consumer ketamine therapy platform offering at-home supervised ketamine sessions for anxiety and depression. Targets the same treatment-resistant patient population with a telehealth-first delivery model that competes with PSI's in-clinic KAP offering.
• Nue Life: Operates ketamine-assisted psychotherapy clinics combined with a digital integration platform for psychedelic therapy. Closely comparable to PSI's TRIP Clinic model and integration therapy service line.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/tripclinics

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Psychedelic Science Institute